Literature DB >> 10914028

Production of recombinant TRAIL and TRAIL receptor: Fc chimeric proteins.

P Schneider1.   

Abstract

The tumor necrosis factor (TNF)/TNF receptor (TNFR) families of ligands and receptors are implicated in a variety of physiological and pathological processes and regulate cellular functions as diverse as proliferation, differentiation, and death. Recombinant forms of these ligands and receptors can act to agonize or antagonize these functions and are therefore useful for laboratory studies and may have clinical applications. A protocol is presented for the expression and purification of dimeric soluble receptors fused to the Fc portion of human IgG1 and of soluble, N-terminally Flag-tagged ligands. Soluble recombinant proteins are easier to handle than membrane-bound proteins and the use of tags greatly facilitates their detection and purification. In addition, some tags may provide enhanced biological activity to the recombinant proteins (mainly by oligomerization and stabilization effects) and facilitate their functional characterization. Expression in bacterial (for selected ligands) and eukaryotic expression systems (for ligands and receptors) was performed using M15 pREP4 bacteria and human embryonic kidney 293 cells, respectively. The yield of purified protein is about 1 mg/liter for the mammalian expression system and several milligrams per liter for the bacterial expression system. Protocols are given for a specific ligand-receptor pair, namely TRAIL (Apo-2L) and TRAIL receptor 2 (DR5), but can be applied to other ligands and receptors of the TNF family.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10914028     DOI: 10.1016/s0076-6879(00)22031-4

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  50 in total

1.  Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin's lymphoma B cells.

Authors:  Guillaume Jacquemin; Virginie Granci; Anne Sophie Gallouet; Najoua Lalaoui; Aymeric Morlé; Elisabetta Iessi; Alexandre Morizot; Carmen Garrido; Thierry Guillaudeux; Olivier Micheau
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

2.  Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level.

Authors:  A Morizot; D Mérino; N Lalaoui; G Jacquemin; V Granci; E Iessi; D Lanneau; F Bouyer; E Solary; B Chauffert; P Saas; C Garrido; O Micheau
Journal:  Cell Death Differ       Date:  2010-11-12       Impact factor: 15.828

3.  Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides.

Authors:  Michael M C Sun; Kevin S Beam; Charles G Cerveny; Kevin J Hamblett; Richard S Blackmore; Michael Y Torgov; Felicia G M Handley; Nathan C Ihle; Peter D Senter; Stephen C Alley
Journal:  Bioconjug Chem       Date:  2005 Sep-Oct       Impact factor: 4.774

4.  Molecular and therapeutic characterization of anti-ectodysplasin A receptor (EDAR) agonist monoclonal antibodies.

Authors:  Christine Kowalczyk; Nathalie Dunkel; Laure Willen; Margret L Casal; Elizabeth A Mauldin; Olivier Gaide; Aubry Tardivel; Giovanna Badic; Anne-Lise Etter; Manuel Favre; Douglas M Jefferson; Denis J Headon; Stéphane Demotz; Pascal Schneider
Journal:  J Biol Chem       Date:  2011-07-05       Impact factor: 5.157

5.  Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria.

Authors:  Katalin Nagy; Kinga Székely-Szüts; Kamel Izeradjene; Leslie Douglas; Mike Tillman; Helga Barti-Juhász; Massimo Dominici; Carlotta Spano; Gian Luca Cervo; Pierfranco Conte; Janet A Houghton; Rudolf Mihalik; László Kopper; István Peták
Journal:  Pathol Oncol Res       Date:  2006-09-23       Impact factor: 3.201

6.  Specific recognition of linear polyubiquitin by A20 zinc finger 7 is involved in NF-κB regulation.

Authors:  Fuminori Tokunaga; Hiroshi Nishimasu; Ryuichiro Ishitani; Eiji Goto; Takuya Noguchi; Kazuhiro Mio; Kiyoko Kamei; Averil Ma; Kazuhiro Iwai; Osamu Nureki
Journal:  EMBO J       Date:  2012-08-28       Impact factor: 11.598

7.  Tissue-specific opposing functions of the inflammasome adaptor ASC in the regulation of epithelial skin carcinogenesis.

Authors:  Stefan K Drexler; Luca Bonsignore; Mark Masin; Aubry Tardivel; Rene Jackstadt; Heiko Hermeking; Pascal Schneider; Olaf Gross; Jurg Tschopp; Amir S Yazdi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-22       Impact factor: 11.205

8.  Direct Thy-1/alphaVbeta3 integrin interaction mediates neuron to astrocyte communication.

Authors:  Tamara Hermosilla; Daniel Muñoz; Rodrigo Herrera-Molina; Alejandra Valdivia; Nicolás Muñoz; Sang-Uk Nham; Pascal Schneider; Keith Burridge; Andrew F G Quest; Lisette Leyton
Journal:  Biochim Biophys Acta       Date:  2008-02-20

9.  Antibodies That Block or Activate Mouse B Cell Activating Factor of the Tumor Necrosis Factor (TNF) Family (BAFF), Respectively, Induce B Cell Depletion or B Cell Hyperplasia.

Authors:  Christine Kowalczyk-Quintas; Sonia Schuepbach-Mallepell; Michele Vigolo; Laure Willen; Aubry Tardivel; Cristian R Smulski; Timothy S Zheng; Jennifer Gommerman; Henry Hess; Jacques-Eric Gottenberg; Fabienne Mackay; Olivier Donzé; Pascal Schneider
Journal:  J Biol Chem       Date:  2016-07-22       Impact factor: 5.157

10.  Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex.

Authors:  Nils Holler; Aubry Tardivel; Magdalena Kovacsovics-Bankowski; Sylvie Hertig; Olivier Gaide; Fabio Martinon; Antoine Tinel; David Deperthes; Silvio Calderara; Therese Schulthess; Jürgen Engel; Pascal Schneider; Jürg Tschopp
Journal:  Mol Cell Biol       Date:  2003-02       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.